The pathogenesis of pituitary tumors

Annual Review of Pathology: Mechanisms of Disease

Volumn 4, Issue , 2009, Pages 97-126

  Asa, Sylvia L ^a   Ezzat, Shereen ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Differentiation; Epigenetics; Oncogenes; Proliferation; Tumor suppressors

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; ADENOVIRUS VECTOR; AROMATIC HYDROCARBON RECEPTOR; CORTICOTROPIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLINE; DOPAMINE 2 RECEPTOR; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; FOLLITROPIN; GLUCOCORTICOID RECEPTOR; GONADORELIN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; GROWTH HORMONE; METHIONINE; PEGVISOMANT; PROTIRELIN; RETINOBLASTOMA PROTEIN; SOMATOMEDIN C; STEROIDOGENIC ACUTE REGULATORY PROTEIN; TRANSCRIPTION FACTOR GATA 2; TRANSFORMING GROWTH FACTOR BETA;

ACTH SECRETING ADENOMA; ADRENALECTOMY; CANCER INCIDENCE; CANCER THERAPY; CARCINOGENESIS; CUSHING DISEASE; ENDOCRINE FUNCTION; EPIGENETICS; GENE MUTATION; GENE THERAPY; GONADOTROPH ADENOMA; GROWTH HORMONE RELEASE; GROWTH HORMONE SECRETING ADENOMA; GROWTH HORMONE SECRETING CELL; HUMAN; HYPOPHYSIS; HYPOPHYSIS ADENOMA; HYPOPHYSIS TUMOR; MOLECULAR GENETICS; NONHUMAN; PATHOLOGIST; PRIORITY JOURNAL; PROLACTINOMA; REVIEW; THYROTROPIN SECRETING ADENOMA; TUMOR CLASSIFICATION; TUMOR DIAGNOSIS; TUMOR SUPPRESSOR GENE; ADENOMA; ANIMAL; CARCINOMA; CELL DIFFERENTIATION; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GENETICS; INCIDENCE; NOMENCLATURE; PATHOLOGY; TREATMENT OUTCOME;

ADENOMA; ANIMALS; CARCINOMA; CELL DIFFERENTIATION; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INCIDENCE; PITUITARY NEOPLASMS; TERMINOLOGY AS TOPIC; TREATMENT OUTCOME;

EID: 66149120642     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev.pathol.4.110807.092259     Document Type: Review

References (150)

1. Ezzat S, Asa SL, CouldwellWT,Barr CE, Dodge WE, et al. 2004. The prevalence of pituitary adenomas: a systematic review. Cancer 101:613-619 (Pubitemid 38970613)
2. Asa SL. 1998.Tumors of the pituitary gland. In Atlas of Tumor Pathology, 3rd ser., fascicle 22.Washington, D.C.: Armed Forces Inst. Pathol.
3. Asa SL, Kovacs K. 1984. Functional morphology of the human fetal pituitary. Pathol. Annu. 19(Pt. 1):275-315
4. Scully KM, Rosenfeld MG. 2002. Pituitary development: regulatory codes in mammalian organogenesis. Science 295:2231-2235 (Pubitemid 34258830)
5. Asa SL, Ezzat S. 1998. The cytogenesis and pathogenesis of pituitary adenomas. Endocr. Rev. 19:798-827
6. Asa SL, Puy LA, Lew AM, Sundmark VC, Elsholtz HP. 1993. Cell type-specific expression of the pituitary transcription activator Pit-1 in the human pituitary and pituitary adenomas. J. Clin. Endocrinol. Metab. 77:1275-1280 (Pubitemid 23345482)
7. Friend KE, Chiou Y-K, Laws ER Jr, Lopes MBS, Shupnik MA. 1993. Pit-1 messenger ribonucleic acid is differentially expressed in human pituitary adenomas. J. Clin. Endocrinol. Metab. 77:1281-1286 (Pubitemid 23345483)
8. Day RN, Koike S, Sakai M, Muramatsu M, Maurer RA. 1990. Both Pit-1 and the estrogen receptor are required for estrogen responsiveness of the rat prolactin gene. Mol. Endocrinol. 4:1964-1971
9. Drolet DW, Scully KM, Simmons DM, Wegner M, Chu K, et al. 1991. TEF, a transcription factor expressed specifically in the anterior pituitary during embryogenesis, defines a new class of leucine zipper proteins. Genes Dev. 5:1739-1753 (Pubitemid 21905871)
10. Dasen JS, O'Connell SM, Flynn SE, Treier M, Gleiberman AS, et al. 1999. Reciprocal interactions of Pit-1 and GATA2 mediate signaling gradient-induced determination of pituitary cell types. Cell 97: 587-598 (Pubitemid 29256962)
11. Lamolet B, Pulichino AM, Lamonerie T, Gauthier Y, Brue T, et al. 2001. A pituitary cell-restricted T box factor, Tpit, activatesPOMCtranscription in cooperation with Pitx homeoproteins. Cell 104:849-859 (Pubitemid 32289278)
12. Ingraham HA, Lala DS, Ikeda Y, Luo X, Shen W-H, et al. 1994. The nuclear receptor steroidogenic factor 1 acts at multiple levels of the reproductive axis. Genes Dev. 8:2302-2312 (Pubitemid 24314292)
13. Asa SL, Bamberger A-M, Cao B, Wong M, Parker KL, Ezzat S. 1996. The transcription activator steroidogenic factor-1 is preferentially expressed in the human pituitary gonadotroph. J. Clin. Endocrinol. Metab. 81:2165-2170 (Pubitemid 26176708)
14. Asa SL, Kovacs K, Bilbao JM. 1983. The pars tuberalis of the human pituitary. A histologic, immunohistochemical, ultrastructural and immunoelectron microscopic analysis. Virchows Arch. [A] 399:49-59 (Pubitemid 13185601)
15. Bergland RM, Page RB. 1979. Pituitary-brain vascular relations: a new paradigm. Science 204:18-24
16. Alexander JM, Biller BMK, Bikkal H, Zervas NT, Arnold A, Klibanski A. 1990. Clinically nonfunctioning pituitary tumors are monoclonal in origin. J. Clin. Invest. 86:336-340 (Pubitemid 20227010)
17. Herman V, Fagin J, Gonsky R, Kovacs K, Melmed S. 1990. Clonal origin of pituitary adenomas. J. Clin. Endocrinol. Metab. 71:1427-1433
18. Schulte HM, Oldfield EH, Allolio B, Katz DA, Berkman RA, Ali IU. 1991. Clonal composition of pituitary adenomas in patients with Cushing's disease: determination by X-chromosome inactivation analysis. J. Clin. Endocrinol. Metab. 73:1302-1308 (Pubitemid 121000707)
19. Gicquel C, LeBouc Y, Luton J-P, Girad F, Bertagna X. 1992. Monoclonality of corticotroph macroadenomas in Cushing's disease. J. Clin. Endocrinol. Metab. 75:472-475
20. Zahedi A, Booth GL, Smyth HS, Farrell WE, Clayton RN, et al. 2001. Distinct clonal composition of primary and metastatic adrencorticotrophic hormone-producing pituitary carcinoma. Clin. Endocrinol. (Oxf.) 55:549-556 (Pubitemid 32955495)
21. Asa SL, Ezzat S. 2002. The pathogenesis of pituitary tumours. Nat. Rev. Cancer 2:836-849
22. Ezzat S, Asa SL. 2006. Mechanisms of disease: The pathogenesis of pituitary tumors. Nat. Clin. Pract. Endocrinol. Metab. 2:220-230
23. Ezzat S, Zheng L, Zhu XF, Wu GE, Asa SL. 2002. Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. J. Clin. Invest. 109:69-78 (Pubitemid 34052543)
24. Yu S, Asa SL,Weigel RJ, Ezzat S. 2003. Pituitary tumor AP-2α recognizes a cryptic promoter in intron 4 of fibroblast growth factor receptor 4. J. Biol. Chem. 278:19597-19602 (Pubitemid 36799142)
25. Ezzat S, Yu S, Asa SL. 2003. Ikaros isoforms in human pituitary tumors: distinct localization, histone acetylation, and activation of the 5′ fibroblast growth factor receptor-4 promoter. Am. J. Pathol. 163:1177-1184 (Pubitemid 37040153)
26. Ezzat S, Zheng L, Asa SL. 2004. Pituitary tumor-derived fibroblast growth factor receptor 4 isoform disrupts neural cell-adhesion molecule/N-cadherin signaling to diminish cell adhesiveness: a mechanism underlying pituitary neoplasia. Mol. Endocrinol. 18:2543-2552 (Pubitemid 39335987)
27. Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, et al. 1997. Positional cloning of the gene for multiple endocrine neoplasia type 1. Science 276:404-407 (Pubitemid 27180699)
28. Zhuang Z, Ezzat S, Vortmeyer AO, Weil R, Oldfield EH, et al. 1997. Mutations of the MEN1 tumor suppressor gene in pituitary tumors. Cancer Res. 57:5446-5451 (Pubitemid 28006744)
29. Asa SL, Somers K, Ezzat S. 1998. The MEN-1 gene is rarely downregulated in pituitary adenomas. J. Clin. Endocrinol. Metab. 83:3210-3212 (Pubitemid 28500959)
30. Kirschner LS, Carney JA, Pack SD,Taymans SE, Giatzakis C, et al. 2000. Mutations of the gene encoding the protein kinase A type I-á regulatory subunit in patients with the Carney complex. Nat. Genet 26:89-92 (Pubitemid 30692864)
31. Yin Z, Williams-Simons L, Parlow AF, Asa S, Kirschner LS. 2008. Pituitary-specific knockout of the Carney complex gene prkar1a leads to pituitary tumorigenesis. Mol. Endocrinol. 22:380-387 (Pubitemid 351185937)
32. Vierimaa O, Georgitsi M, Lehtonen R, Vahteristo P, Kokko A, et al. 2006. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 312:1228-1230 (Pubitemid 43801151)
33. DiGiovanni R, Serra S, Ezzat S, Asa SL. 2007. AIP mutations are not identified in patients with sporadic pituitary adenomas. Endocr. Pathol. 18:76-78 (Pubitemid 47574990)
34. Billestrup N, Swanson LW, Vale W. 1986. Growth hormone-releasing factor stimulates proliferation of somatotrophs in vitro. Proc. Natl. Acad. Sci. USA 83:6854-6857 (Pubitemid 16002331)
35. Godfrey P, Rahal J, Beamer W, Copeland N, Jenkins N, Mayo K. 1993. GHRH receptor of little mice contains a missense mutation in the extracellular domain that disrupts receptor function. Nat. Genet 4:227-232 (Pubitemid 23205169)
36. Stefaneanu L, Kovacs K, Horvath E, Asa SL, Losinski NE, et al. 1989. Adenohypophysial changes in mice transgenic for human growth hormone-releasing factor: a histological, immunocytochemical, and electron microscopic investigation. Endocrinology 125:2710-2718 (Pubitemid 19279463)
37. Thorner MO, Perryman RL, Cronin MJ, Rogol AD, Draznin M, et al. 1982. Somatotroph hyperplasia: successful treatment of acromegaly by removal of a pancreatic islet tumor secreting a growth hormone- releasing factor. J. Clin. Invest. 70:965-977
38. Sano T, Asa SL, Kovacs K. 1988. Growth hormone-releasing hormone-producing tumors: clinical, biochemical, and morphological manifestations. Endocr. Rev. 9:357-373
39. Levy A, Lightman SL. 1992. Growth hormone-releasing hormone transcripts in human pituitary adenomas. J. Clin. Endocrinol. Metab. 74:1474-1476
40. Joubert D, Benlot C, Lagoguey A, Garnier P, Brandi AM, et al. 1989. Normal and growth hormone (GH)-secreting adenomatous human pituitaries release somatostatin and GH-releasing hormone. J. Clin. Endocrinol. Metab. 68:572-577 (Pubitemid 19081431)
41. Thapar K, Kovacs K, Stefaneanu L, Scheithauer B, Killinger D, et al. 1997. Overexpression of the growthhormone- releasing hormone gene in acromegaly-associated pituitary tumors. An event associated with neoplastic progression and aggressive behavior. Am. J. Pathol. 151:769-784 (Pubitemid 27385609)
42. Ezzat S, Asa SL, Stefaneanu L, Whittom R, Smyth HS, et al. 1994. Somatotroph hyperplasia without pituitary adenoma associated with a long-standing growth hormone-releasing hormone-producing bronchial carcinoid. J. Clin. Endocrinol. Metab. 78:555-560 (Pubitemid 24083291)
43. Lee EJ, Kotlar TJ, Ciric I, Lee MK, Lim SK, et al. 2001. Absence of constitutively activating mutations in the GHRH receptor in GH-producing pituitary tumors. J. Clin. Endocrinol. Metab. 86:3989-3995 (Pubitemid 32756009)
44. Hashimoto K, Koga M, Motomura T, Kasayama S, Kouhara H, et al. 1995. Identification of alternatively spliced messenger ribonucleic acid encoding truncated growth hormone-releasing hormone receptor in human pituitary adenomas. J. Clin. Endocrinol. Metab. 80:2933-2939
45. Bertherat J, Chanson P, Dewailly D, Dupuy M, Jaquet P, et al. 1993. Somatostatin receptors, adenylate cyclase activity, and growth hormone (GH) response to octreotide in GH-secreting adenomas. J. Clin. Endocrinol. Metab. 77:1577-1583 (Pubitemid 24000917)
46. Danila DC, Haidar JN, Zhang X, Katznelson L, Culler MD, Klibanski A. 2001. Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors. J. Clin. Endocrinol. Metab. 86:2976-2981 (Pubitemid 32673451)
47. Ballare E, Persani L, Lania AG, Filopanti M, Giammona E, et al. 2001. Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment. J. Clin. Endocrinol. Metab. 86:3809-3814 (Pubitemid 32755981)
48. Levy L, Bourdais J, Mouhieddine B, Benlot C, Villares S, et al. 1993. Presence and characterization of the somatostatin precursor in normal human pituitaries and in growth hormone-secreting adenomas. J. Clin. Endocrinol. Metab. 76:85-90 (Pubitemid 23027558)
49. Filopanti M, Ballare E, Lania AG, Bondioni S, Verga U, et al. 2004. Loss of heterozygosity at the SS receptor type 5 locus in human GH- and TSH-secreting pituitary adenomas. J. Endocrinol. Invest 27:937-942 (Pubitemid 40124189)
50. Kola B, Korbonits M, Diaz-Cano S, Kaltsas G, Morris DG, et al. 2003. Reduced expression of the growth hormone and type 1 insulin-like growth factor receptors in human somatotroph tumours and an analysis of possible mutations of the growth hormone receptor. Clin. Endocrinol. (Oxf.) 59:328-338 (Pubitemid 37046986)
51. Vallar L, Spada A, Giannattasio G. 1987. Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. Nature 330:566-568 (Pubitemid 17164352)
52. Landis CA, Masters SB, Spada A, Pace AM, Bourne HR, Vallar L. 1989. GTPase inhibiting mutations activate the α-chain of Gs and stimulate adenylate cyclase in human pituitary tumors. Nature 340:692-696 (Pubitemid 19214389)
53. Hayward BE, Barlier A, Korbonits M, Grossman AB, Jacquet P, et al. 2001. Imprinting of the Gsα gene GNAS1 in the pathogenesis of acromegaly. J. Clin. Invest. 107:R31-36 (Pubitemid 32225362)
54. Spada A, Arosio M, Bochicchio D, Bazzoni N, Vallar L, et al. 1990. Clinical, biochemical and morphological correlates in patients bearing growth hormone-secreting pituitary tumors with or without constitutively active adenylyl cyclase. J. Clin. Endocrinol. Metab. 71:1421-1426 (Pubitemid 120032754)
55. Asa SL, DiGiovanni R, Jiang J,Ward ML, Loesch K, et al. 2007. A growth hormone receptor mutation impairs growth hormone autofeedback signaling in pituitary tumors. Cancer Res. 67:7505-7511 (Pubitemid 47206580)
56. Ezzat S, Kontogeorgos G, Redelmeier DA, Horvath E, Harris AG, Kovacs K. 1995. In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomas to octreotide. Eur. J. Endocrinol. 133:686-690 (Pubitemid 26017312)
57. Bhayana S, Booth GL, Asa SL, Kovacs K, Ezzat S. 2005. The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. J. Clin. Endocrinol. Metab. 90:6290-6295 (Pubitemid 41606558)
58. Asa SL, Coschigano KT, Bellush L, Kopchick JJ, Ezzat S. 2000. Evidence for growth hormone (GH) autoregulation in pituitary somatotrophs in GH antagonist-transgenic mice and GH receptor-deficient mice. Am. J. Pathol. 156:1009-1015 (Pubitemid 30626958)
59. Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J. 1997. Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J. Clin. Endocrinol. Metab. 82:2102-2107 (Pubitemid 27287568)
60. Lohrer P, Gloddek J, Hopfner U, Losa M, Uhl E, et al. 2001. Vascular endothelial growth factor production and regulation in rodent and human pituitary tumor cells in vitro. Neuroendocrinology 74: 95-105 (Pubitemid 32727576)
61. Heaney AP, Fernando M, Melmed S. 2002. Functional role of estrogen in pituitary tumor pathogenesis. J. Clin. Invest. 109:277-283 (Pubitemid 34083748)
62. Shen ES, Hardenburg JL, Meade EH, Arey BJ, Merchenthaler I, Lopez FJ. 1999. Estradiol induces galanin gene expression in the pituitary of the mouse in an estrogen receptor α-dependent manner. Endocrinology 140:2628-2631 (Pubitemid 32248700)
63. Lee EJ, Jakacka M, Duan WR, Chien PY, Martinson F, et al. 2001. Adenovirus-directed expression of dominant negative estrogen receptor induces apoptosis in breast cancer cells and regression of tumors in nude mice. Mol. Med. 7:773-782 (Pubitemid 34175299)
64. Asa SL, Penz G, Kovacs K, Ezrin C. 1982. Prolactin cells in the human pituitary. A quantitative immunocytochemical analysis. Arch. Pathol. Lab. Med. 106:360-363 (Pubitemid 12048248)
65. Molitch ME. 2003. Pituitary tumors and pregnancy. Growth Horm. IGF Res. 13(Suppl. A):S38-44
66. Kovacs K, Stefaneanu L, Ezzat S, Smyth HS. 1994. Prolactin-producing pituitary adenoma in amale-tofemale transsexual patient with protracted estrogen administration. A morphologic study. Arch. Pathol. Lab. Med. 118:562-565 (Pubitemid 24176837)
67. Testa G, Vegetti W, Motta T, Alagna F, Bianchedi D, et al. 1998. Two-year treatment with oral contraceptives in hyperprolactinemic patients. Contraception 58:69-73 (Pubitemid 28449359)
68. Schechter J, Goldsmith P, Wilson C, Weiner R. 1988. Morphological evidence for the presence of arteries in human prolactinomas. J. Clin. Endocrinol. Metab. 67:713-719 (Pubitemid 18238444)
69. Kelly MA, Rubinstein M, Asa SL, Zhang G, Saez C, et al. 1997. Pituitary lactotroph hyperplasia and chronic hyperprolactinemia in dopamine D2 receptor-deficient mice. Neuron 19:103-113 (Pubitemid 27332997)
70. Asa SL, Kelly MA, Grandy DK, Low MJ. 1999. Pituitary lactotroph adenomas develop after prolonged lactotroph hyperplasia in dopamine D2 receptor-deficient mice. Endocrinology 140:5348-5355 (Pubitemid 30687146)
71. Fiorentini C, Guerra N, Facchetti M, Finardi A, Tiberio L, et al. 2002. Nerve growth factor regulates dopamine D(2) receptor expression in prolactinoma cell lines via p75(NGFR)-mediated activation of nuclear factor-êB. Mol. Endocrinol. 16:353-366 (Pubitemid 34131230)
72. Devost D, Boutin JM. 1999. Autoregulation of the rat prolactin gene in lactotrophs. Mol. Cell Endocrinol. 158:99-109
73. Kelly PA, Binart N, Lucas B, Bouchard B, Goffin V. 2001. Implications of multiple phenotypes observed in prolactin receptor knockout mice. Front. Neuroendocrinol. 22:140-145 (Pubitemid 32281580)
74. Schuff KG, Hentges ST, Kelly MA, Binart N, Kelly PA, et al. 2002. Lack of prolactin receptor signaling in mice results in lactotroph proliferation and prolactinomas by dopamine-dependent and -independent mechanisms. J. Clin. Invest. 110:973-981
75. Scheithauer BW, Kovacs K, Randall RV, Ryan N. 1985. Pituitary gland in hypothyroidism. Histologic and immunocytologic study. Arch. Pathol. Lab. Med. 109:499-504 (Pubitemid 15032579)
76. Yamada M, Monden T, Satoh T, Sato N, Murakami M, et al. 1993. Pituitary adenomas of patients with acromegaly express thyrotropin-releasing hormone receptor messenger RNA cloning and functional expression of the human thyrotropin-releasing hormone receptor gene. Biochem. Biophys. Res. Commun. 195:737-745 (Pubitemid 23280478)
77. Gittoes NJL, McCabe CJ, Verhaeg J, Sheppard MC, Franklyn JA. 1997. Thyroid hormone and estrogen receptor expression in normal pituitary and nonfunctioning tumors of the anterior pituitary. J. Clin. Endocrinol. Metab. 82:1960-1967 (Pubitemid 127495218)
78. Ando S, Sarlis NJ, Krishnan J, Feng X, Refetoff S, et al. 2001. Aberrant alternative splicing of thyroid hormone receptor in a TSH-secreting pituitary tumor is a mechanism for hormone resistance. Mol. Endocrinol. 15:1529-1538 (Pubitemid 32826405)
79. Abel ED, Boers ME, Pazos-Moura C, Moura E, Kaulbach H, et al. 1999. Divergent roles for thyroid hormone receptor β isoforms in the endocrine axis and auditory system. J. Clin. Invest. 104:291-300
80. BrinkmeierML,Stahl JH, Gordon DF, Ross BD, Sarapura VD, et al. 2001. Thyroid hormone-responsive pituitary hyperplasia independent of somatostatin receptor 2. Mol. Endocrinol. 15:2129-2136
81. Carey RM, Varma SK, Drake CR Jr, Thorner MO, Kovacs K, et al. 1984. Ectopic secretion of corticotropin-releasing factor as a cause of Cushing's syndrome. A clinical, morphologic, and biochemical study. N. Engl. J. Med. 311:13-20
82. Stenzel-Poore MP, Cameron VA, Vaughan J, Sawchenko PE, Vale W. 1992. Development of Cushing's syndrome in corticotropin-releasing factor transgenic mice. Endocrinology 130:3378-3386
83. Scheithauer BW, Kovacs K, Randall RV. 1983. The pituitary gland in untreated Addison's disease. A histologic and immunocytologic study of 18 adenohypophyses. Arch. Pathol. Lab. Med. 107:484-487
84. Bamberger CM, Schulte HM, Chrousos GP. 1996. Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids. Endocr. Rev. 17:245-261
85. Hurley DM, Accili D, Stratakis CA, Karl M, Vamvakopoulos N, et al. 1991. Point mutation causing a single amino acid substitution in the hormone binding domain of the glucocorticoid receptor in familial glucocorticoid resistance. J. Clin. Invest. 87:680-686
86. Karl M, Lamberts SWJ, Koper JW, Katz DA, Huizenga NE, et al. 1996. Cushing's disease preceded by generalized glucocorticoid resistance: clinical consequences of a novel dominant-negative glucocorticoid receptor mutation. Proc. Assoc. Am. Phys. 108:296-307
87. Karl M, von Wichert G, Kempter E, Katz DA, Reincke M, et al. 1996. Nelson's syndrome associated with a somatic frame shift mutation in the glucocorticoid receptor gene. J. Clin. Endocrinol. Metab. 81:124-129
88. Kovacs K, Horvath E, Rewcastle NB, Ezrin C. 1980. Gonadotroph cell adenoma of the pituitary in a woman with long-standing hypogonadism. Arch. Gynecol. 229:57-65 (Pubitemid 10137099)
89. Nicolis G, Shimshi M, Allen C, Halmi NS, Kourides IA. 1988. Gonadotropin-producing pituitary adenoma in a man with long-standing primary hypogonadism. J. Clin. Endocrinol. Metab. 66:237-241 (Pubitemid 18027758)
90. Danila DC, Inder WJ, Zhang X, Alexander JM, Swearingen B, et al. 2000. Activin effects on neoplastic proliferation of human pituitary tumors. J. Clin. Endocrinol. Metab. 85:1009-1015 (Pubitemid 32269341)
91. Haddad G, Penabad JL, Bashey HM, Asa SL, Gennarelli TA, et al. 1994. Expression of activin/inhibin subunit messenger ribonucleic acids by gonadotroph adenomas. J. Clin. Endocrinol. Metab. 79:1399-1403 (Pubitemid 24369856)
92. Penabad JL, Bashey HM, Asa SL, Haddad G, Davis KD, et al. 1996. Decreased follistatin gene expression in gonadotroph adenomas. J. Clin. Endocrinol. Metab. 81:3397-3403 (Pubitemid 26296222)
93. Zhou Y, Sun H, Danila DC, Johnson SR, Sigai DP, et al. 2000. Truncated activin type I receptor Alk4 isoforms are dominant negative receptors inhibiting activin signaling. Mol. Endocrinol. 14:2066-2075
94. Karga HJ, Alexander JM, Hedley-Whyte ET, Klibanski A, Jameson JL. 1992. Ras mutations in human pituitary tumors. J. Clin. Endocrinol. Metab. 74:914-919
95. Cai WY, Alexander JM, Hedley-Whyte ET, Scheithauer BW, Jameson JL, et al. 1994. Ras mutations in human prolactinomas and pituitary carcinomas. J. Clin. Endocrinol. Metab. 78:89-93 (Pubitemid 24026753)
96. Zou H, McGarry TJ, Bernal T, Kirschner MW. 1999. Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science 285:418-422 (Pubitemid 29343966)
97. Pei L, Melmed S. 1997. Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol. Endocrinol. 11:433-441 (Pubitemid 27147011)
98. Ramos-Morales F, Dominguez A, Romero F, Luna R, Multon MC, et al. 2000. Cell cycle regulated expression and phosphorylation of hpttg proto-oncogene product. Oncogene 19:403-409 (Pubitemid 30077341)
99. +/- pituitary tumorigenesis. Mol. Endocrinol. 19:2371-2379
100. Martin A, Odajima J, Hunt SL, Dubus P, Ortega S, et al. 2005. Cdk2 is dispensable for cell cycle inhibition and tumor suppression mediated by p27(Kip1) and p21(Cip1). Cancer Cell 7:591-598 (Pubitemid 40799251)
101. Gospodarowicz D, Ferrara N, Schweigerer L, Neufeld G. 1987. Structural characterization and biological functions of fibroblast growth factor. Endocr. Rev. 8:95-114 (Pubitemid 18005478)
102. Ferrara N, Schweigerer L, Neufeld G, Mitchell R, Gospodarowicz D. 1987. Pituitary follicular cells produce basic fibroblast growth factor. Proc. Natl. Acad. Sci. USA 84:5773-5777 (Pubitemid 18013014)
103. Celli G, LaRochelle WJ, Mackem S, Sharp R, Merlino G. 1998. Soluble dominant-negative receptor uncovers essential roles for fibroblast growth factors in multi-organ induction and patterning. EMBO J. 17:1642-1655 (Pubitemid 28119118)
104. Ezzat S, Smyth HS, Ramyar L, Asa SL. 1995. Heterogeneous in vivo and in vitro expression of basic fibroblast growth factor by human pituitary adenomas. J. Clin. Endocrinol. Metab. 80:878-884
105. Li Y, Koga M, Kasayama S, Matsumoto K, Arita N, et al. 1992. Identification and characterization of high molecular weight forms of basic fibroblast growth factor in human pituitary adenomas. J. Clin. Endocrinol. Metab. 75:1436-1441 (Pubitemid 23001398)
106. Zimering MB, Katsumata N, Sato Y, Brandi ML, Aurbach GD, et al. 1993. Increased basic fibroblast growth factor in plasma from multiple endocrine neoplasia type 1: relation to pituitary tumor. J. Clin. Endocrinol. Metab. 76:1182-1187 (Pubitemid 23155433)
107. Asa SL, Ramyar L, Murphy PR, Li AW, Ezzat S. 2001. The endogenous fibroblast growth factor-2 antisense gene product regulates pituitary cell growth and hormone production. Mol. Endocrinol. 15: 589-599 (Pubitemid 32324440)
108. Heaney AP, Horwitz GA,Wang Z, Singson R, Melmed S. 1999. Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. Nat. Med. 5:1317-1321 (Pubitemid 29535612)
109. Itoh N, Ornitz DM. 2004. Evolution of the Fgf and Fgfr gene families. Trends Genet. 20:563-569 (Pubitemid 39314564)
110. De Moerlooze L, Spencer-Dene B, Revest J, Hajihosseini M, Rosewell I, Dickson C. 2000. An important role for the IIIb isoform of fibroblast growth factor receptor 2 (FGFR2) in mesenchymal-epithelial signalling during mouse organogenesis. Development 127:483-492 (Pubitemid 30093396)
111. Abbass SAA, Asa SL, Ezzat S. 1997. Altered expression of fibroblast growth factor receptors in human pituitary adenomas. J. Clin. Endocrinol. Metab. 82:1160-1166 (Pubitemid 27166658)
112. Zhu X, Lee K, Asa SL, Ezzat S. 2007. Epigenetic silencing through DNA and histone methylation of fibroblast growth factor receptor 2 in neoplastic pituitary cells. Am. J. Pathol. 170:1618-1628 (Pubitemid 47339306)
113. Zhu X, Asa SL, Ezzat S. 2008. FGFR2 and estrogen control the balance of histone 3 modifications targeting MAGE-A3 in pituitary neoplasia. Clin. Cancer Res. 14:1984-1996 (Pubitemid 351551107)
114. Daniel L, Trouillas J, Renaud W, Chevallier P, Gouvernet J, et al. 2000. Polysialylated-neural cell adhesion molecule expression in rat pituitary transplantable tumors (spontaneous mammotropic transplantable tumor inWistar-Furth rats) is related to growth rate and malignancy. Cancer Res. 60:80-85 (Pubitemid 30058735)
115. Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA,Weinberg RA. 1992. Effects of an Rb mutation in the mouse. Nature 359:295-300
116. Cryns VL, Alexander JM, Klibanski A, Arnold A. 1993. The retinoblastoma gene in human pituitary tumors. J. Clin. Endocrinol. Metab. 77:644-646 (Pubitemid 23298641)
117. Pei L, Melmed S, Scheithauer B, Kovacs K, Benedict WF, Prager D. 1995. Frequent loss of heterozygosity at the retinoblastoma susceptibility gene (RB) locus in aggressive pituitary tumors: evidence for a chromosome 13 tumor suppressor gene other than RB. Cancer Res. 55:1613-1616
118. Woloschak M, Yu A, Xiao J, Post KD. 1996. Abundance and state of phosphorylation of the retinoblastoma gene product in human pituitary tumors. Int. J. Cancer 67:16-19 (Pubitemid 26236062)
119. Bates AS, Farrell WE, Bicknell EJ, McNicol AM, Talbot AJ, et al. 1997. Allelic deletion in pituitary adenomas reflects aggressive biological activity and has potential value as a prognostic marker. J. Clin. Endocrinol. Metab. 82:818-824
120. Tsai KY, MacPherson D, Rubinson DA, Nikitin AY, Bronson R, et al. 2002. ARF mutation accelerates pituitary tumor development in Rb+/- mice. Proc. Natl. Acad. Sci. USA 99:16865-16870 (Pubitemid 36034064)
121. Lasorella A, Rothschild G, Yokota Y, Russell RG, Iavarone A. 2005. Id2 mediates tumor initiation, proliferation, and angiogenesis in Rb mutant mice. Mol. Cell Biol. 25:3563-3574 (Pubitemid 40559563)
122. Buckley N, Bates AS, Broome JC, Strange RC, Perrett CW, et al. 1994. p53 protein accumulation in Cushing's adenomas and invasive nonfunctional adenomas. J. Clin. Endocrinol. Metab. 79:1513-1516 (Pubitemid 24369875)
123. Sumi T, Stefaneanu L, Kovacs K, Asa SL, Rindi G. 1993. Immunohistochemical study of p53 protein in human and animal pituitary tumors. Endocr. Pathol. 4:95-99 (Pubitemid 23099531)
124. Thapar K, Scheithauer BW, Kovacs K, Pernicone PJ, Laws ER Jr. 1996. p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Neurosurgery 38:765-771 (Pubitemid 26087884)
125. Levy A, Hall L, Yeundall WA, Lightman SL. 1994. p53 gene mutations in pituitary adenomas: rare events. Clin. Endocrinol. (Oxf.) 41:809-814
126. Amar AP, Hinton DR, Krieger MD, Weiss MH. 1999. Invasive pituitary adenomas: significance of proliferation parameters. Pituitary 2:117-122
127. Sherr CJ, Roberts JM. 1995. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 9: 1149-1163
128. Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, et al. 1996. Mice lacking p27Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85:707-720 (Pubitemid 26181050)
129. Kip1. Cell 85:721-732
130. Kip1-deficient mice. Cell 85:733-744
131. Kip1 mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. Genes Dev. 12:2899-2911
132. Kip1 in human pituitary adenomas. Eur. J. Endocrinol. 140:250-255
133. Dahia PL, Aguiar RC, Honegger J, Fahlbush R, Jordan S, et al. 1998. Mutation and expression analysis of the p27/Kip1 gene in corticotrophin- secreting tumours. Oncogene 16:69-76 (Pubitemid 28043509)
134. Liu W, Asa SL, Ezzat S. 2002. Vitamin D and its analog EB1089 induce p27 accumulation and diminish association of p27 with Skp2 independent of PTEN in pituitary corticotroph cells. Brain Pathol. 12: 412-419 (Pubitemid 35154928)
135. Kip1 in mice. Mol. Cell Biol. 21:1319-1328
136. Woloschak M, Yu A, Post KD. 1997. Frequent inactivation of the p16 gene in human pituitary tumors by gene methylation. Mol. Carcinog. 19:221-224 (Pubitemid 27391999)
137. Frost SJ, Simpson DJ, Clayton RN, Farrell WE. 1999. Transfection of an inducible p16/CDKN2A construct mediates reversible growth inhibition and G1 arrest in the AtT20 pituitary tumor cell line. Mol. Endocrinol. 13:1801-1810
138. Zhang X, Sun H, Danila DC, Johnson SR, Zhou Y, et al. 2002. Loss of expression ofGADD45γ, a growth inhibitory gene, in human pituitary adenomas: implications for tumorigenesis. J. Clin. Endocrinol. Metab. 87:1262-1267 (Pubitemid 36121097)
139. Bahar A, Bicknell JE, Simpson DJ, Clayton RN, Farrell WE. 2004. Loss of expression of the growth inhibitory gene GADD45γ, in human pituitary adenomas, is associated with CpG island methylation. Oncogene 23:936-944 (Pubitemid 38250939)
140. Zhao J, Dahle D, Zhou Y, Zhang X, Klibanski A. 2005. Hypermethylation of the promoter region is associated with the loss of MEG3 gene expression in human pituitary tumors. J. Clin. Endocrinol. Metab. 90:2179-2186 (Pubitemid 40586259)
141. Bahar A, Simpson DJ, Cutty SJ, Bicknell JE, Hoban PR, et al. 2004. Isolation and characterization of a novel pituitary tumor apoptosis gene. Mol. Endocrinol. 18:1827-1839 (Pubitemid 38859588)
142. Georgopoulos K,Winandy S, Avitahl N. 1997. The role of the Ikaros gene in lymphocyte development and homeostasis. Annu. Rev. Immunol. 15:155-176 (Pubitemid 27169278)
143. Ezzat S, Mader R, Yu S, Ning T, Poussier P, Asa SL. 2005. Ikaros integrates endocrine and immune system development. J. Clin. Invest. 115:1021-1029 (Pubitemid 40489407)
144. Ezzat S, Mader R, Fischer S, Yu S, Ackerley C, Asa SL. 2006. An essential role for the hematopoietic transcription factor Ikaros in hypothalamic- pituitary-mediated somatic growth. Proc. Natl. Acad. Sci. USA 103:2214-2219 (Pubitemid 43271649)
145. Ezzat S, Yu S, Asa SL. 2005. The zinc finger Ikaros transcription factor regulates pituitary growth hormone and prolactin gene expression through distinct effects on chromatin accessibility. Mol. Endocrinol. 19:1004-1011 (Pubitemid 40397064)
146. Ezzat S, Zhu X, Loeper S, Fischer S, Asa SL. 2006. Tumor-derived Ikaros 6 acetylates the Bcl-XL promoter to up-regulate a survival signal in pituitary cells. Mol. Endocrinol. 20:2976-2986 (Pubitemid 44833549)
147. Loeper S, Asa SL, Ezzat S. 2008. Ikaros modulates cholesterol uptake: a link between tumor suppression and differentiation. Cancer Res. 68:3715-3723
148. +/- mice. Nat. Med. 2:1316-1321
149. Freese A, During MJ, Davidson BL, Gennarelli TA, Kaplitt MG, et al. 1996. Transfection of human lactotroph adenoma cells with an adenovirus vector expressing tyrosine hydroxylase decreases prolactin release. J. Clin. Endocrinol. Metab. 81:2401-2404 (Pubitemid 26175976)
150. Ezzat S, Zheng L, Winer D, Asa SL. 2006. Targeting N-cadherin through fibroblast growth factor receptor - 4: distinct pathogenetic and therapeutic implications. Mol. Endocrinol. 20:2965-2975 (Pubitemid 44833547)